MAPT and Alzheimer disease: The low levels of neuropathology, and corresponding PET signal, during the early phase of tau aggregation seen in preclinical AD preceding cognitive impairment requires accurate quantitative of [F-18]MK6240 binding to characterize the role of tau during this critical stage of disease progression.